Filtered By:
Cancer: Brain Cancers

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 538 results found since Jan 2013.

Current Development of siRNA Bioconjugates: From Research to the Clinic
In this study, it was shown that the main factor determining the nature of the biodistribution of conjugates is their lipophilicity. Conjugates of siRNA with lower lipophilicity; i.e., derivatives of retinoic acid, lithocholic acid, and docosahexanoic acid with greater efficiency than cholesterol conjugates accumulated in the kidneys, bladder, and lungs of the mouse after subcutaneous injection (Biscans et al., 2018). This fact is consistent with previous data that showed that more lipophilic conjugates bind more efficiently to serum components, and thus are not excreted by the kidneys (Wolfrum et al., 2007; Osborn et al.,...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

Multilevel chitosan-gelatin particles loaded with P4HA1 siRNA suppress glioma development
Drug Deliv Transl Res. 2023 Sep 4. doi: 10.1007/s13346-023-01422-8. Online ahead of print.ABSTRACTIt has been reported that prolyl 4-hydroxylase subunit alpha 1 (P4HA1) promoted tumor growth and metastasis of glioma; thus, targeting P4HA1 may be a promising therapeutic strategy against glioma. In consideration of the instability of siRNA in vivo, the chitosan-gelatin microspheres loaded with P4HA1 siRNA (P4HA1 siRNA@CGM) were employed. Firstly, the gel electrophoresis and hemolytic test were performed to assess the stability and blood compatibility of P4HA1 siRNA@CGM. Then, methyl thiazolyl tetrazolium (MTT), cell colony f...
Source: Cell Research - September 4, 2023 Category: Cytology Authors: Yiting Zhou Jiajia Tian Yi Zhu Yating Zhang Xudong Zhao Source Type: research

Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles
This study aims to investigate the therapeutic effects of intravenous administration of T7 peptide modified core-shell nanoparticles (named T7-LPC/siRNA NPs) on brain tumors. Layer-by-layer assembling of protamine/chondroitin sulfate/siRNA/cationic liposomes followed by T7 peptide modification has been carried out in order to obtain a targeted siRNA delivery system. In vitro cellular uptake experiments demonstrated a higher intracellular fluorescence intensity of siRNA in brain microvascular endothelial cells (BMVECs) and U87 glioma cells when treated with T7-LPC/siRNA NPs compared with PEG-LPC/siRNA NPs. In the co-culture...
Source: International Journal of Pharmaceutics - July 14, 2016 Category: Drugs & Pharmacology Source Type: research

New Paradigms on siRNA Local Application.
Abstract Small interfering RNA (siRNA) functions through pairing with specific mRNA sequences and results in mRNA degradation, which is becoming a potential therapeutic approach for many diseases caused by altered gene expression. The delivery is a major problem for siRNA application due to its rapid degradation in blood circulation. Various strategies have been proposed to help cellular uptake of siRNA/short or small hairpin RNA (shRNA) successfully. Here we reviewed the recent published data regarding local applications of siRNA. Compared with systematic delivery methods, local delivery of siRNA/shRNA demonstrat...
Source: BMB Reports - July 31, 2014 Category: Biochemistry Authors: Pan M, Ni J, He H, Gao S, Duan X Tags: BMB Rep Source Type: research

Effect of Inducible Co-Stimulatory Molecule siRNA in Cerebral Infarction Rat Models.
CONCLUSIONS ICOS siRNA can protect brain tissues from ischemia injuries after cerebral infarction, improve limb movement and coordination, lower the mortality rate of rats, and inhibit T cell-induced cytokines. These results collectively suggest the potential treatment efficacy of ICOS siRNA against cerebral infarction. PMID: 26436531 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - October 6, 2015 Category: Research Tags: Med Sci Monit Source Type: research

siRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery.
Abstract As the population ages, brain pathologies such as neurodegenerative diseases and brain cancer increase their incidence, being the need to find successful treatments of upmost importance. Drug delivery to the central nervous system (CNS) is required in order to reach diseases causes and treat them. However, biological barriers, mainly blood-brain barrier (BBB), are the key obstacles that prevent the effectiveness of possible treatments due to their ability to strongly limit the perfusion of compounds into the brain. Over the past decades, new approaches towards overcoming BBB and its efflux transporters ha...
Source: Ageing Research Reviews - March 18, 2015 Category: Genetics & Stem Cells Authors: Gomes MJ, Martins S, Sarmento B Tags: Ageing Res Rev Source Type: research

Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma.
In conclusion, prepared DP-CLPs-PTX-siRNA nanocomplex selectively induced CD133+ glioma stem cell apoptosis in vitro and in vivo exhibits great potential for targeted imaging and therapy of brain glioma stem cells. PMID: 30269613 [PubMed - in process]
Source: Drug Delivery - October 3, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research

Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
Abstract Activation of signal transducer and activator of transcription3 (STAT3) is a hallmark of several types of cancer. Failure to inhibit STAT3 expression by injection of siRNA for STAT3 directly to Balb/c mice led us to adopt alternative means. We formulated nanoparticle-based encapsulation of siRNA (NsiRNA) with polyethylenimine (PEI) and poly (lactide-co-glycolide) (PLGA) and characterized them. The siRNA treated and NsiRNA-treated cells were subjected separately to different assay systems. We also checked if NsiRNA could cross the Blood Brain Barrier (BBB). Cell viability reduced dramatically in A549 cells...
Source: Toxicology Letters - January 16, 2014 Category: Toxicology Authors: Das J, Das S, Paul A, Samadder A, Bhattacharyya SS, Khuda-Bukhsh AR Tags: Toxicol Lett Source Type: research

Intranasal Brain Delivery of Cationic Nanoemulsion-Encapsulated TNFα siRNA in Prevention of Experimental Neuroinflammation
Publication date: Available online 6 January 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Sunita Yadav, Srujan K. Gandham, Riccardo Panicucci, Mansoor M. Amiji Neuroinflammation is a hallmark of acute and chronic neurodegenerative disorders. Activated microglia and secreted factors such as tumor necrosis factor-alpha (TNFα) are key mediators of neuroinflammation and may contribute to neuronal dysfunction. The main aim of this study was to evaluate the therapeutic efficacy of intranasal cationic nanoemulsions encapsulating an anti-TNFα siRNA, for potential anti-inflammatory therapy, test...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - January 12, 2016 Category: Nanotechnology Source Type: research

Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy.
Abstract Tumor angiogenesis involves multiple signaling pathways that provide potential therapeutic targets to inhibit tumor growth and metastasis. Regarding the significant role of vascular endothelial growth factor (VEGF) in angiogenesis and tumor progression, VEGF sequence-specific small interfering RNA (siRNA) for antiangiogenic tumor therapy are under development. In the present study, a dual-modified liposomes (At-Lp) was designed by attaching two receptor-specific peptides, i.e. low-density lipoprotein receptor-related protein receptor (Angiopep) for brain tumor targeting and neuropilin-1 receptor (tLyP-1) ...
Source: Current Gene Therapy - June 12, 2014 Category: Genetics & Stem Cells Authors: Yang Z, Xiang B, Dong D, Wang Z, Jingquan L, Xianrong Q Tags: Curr Gene Ther Source Type: research

Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in-vitro analysis.
Abstract In man brain cancer is an aggressive, malignant form of tumor, it is highly infiltrative in nature, is associated with cellular heterogeneity and affects cerebral hemispheres of the brain. Current drug therapies are inadequate and an unmet clinical need exists to develop new improved therapeutics. The ability to silence genes associated with disease progression by using short interfering RNA (siRNA) presents the potential to develop safe and effective therapies. In this work, in order to protect the siRNA from degradation, promote cell specific uptake and enhance gene silencing efficiency, a PEGylated cyc...
Source: European Journal of Pharmaceutical Sciences - February 19, 2015 Category: Drugs & Pharmacology Authors: Gooding M, Malhotra M, McCarthy DJ, Godinho BM, Cryan JF, Darcy R, O'Driscoll CM Tags: Eur J Pharm Sci Source Type: research

RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
This study provides possible application of pRNA-3WJ RNP for specific delivery of therapeutics such as siRNA, microRNA and/or chemotherapeutic drugs into glioblastoma cells without inflicting collateral damage to healthy tissues. PMID: 25885522 [PubMed - as supplied by publisher]
Source: Oncotarget - April 19, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research